Glycemic variability and continuous monitoring of glycemia

Czech version

Authors: Martin Prázný; Jan Šoupal
Authors‘ workplace: III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2014; 60(9): 757-763
Category:

Overview

Blood glucose levels are not constant in ther human body even in physiological status. It fluctuates depending on food intake, exercise, psychological and other factors. Normally it fluctuates between 3.9 to 7.5 mmol/l and in fasting in the standard conditions it does not exceed even more narrow range 3.9 to 5.5 mmol/l. Fluctuations are more pronounced in patient with diabetes. Hyperglycemia is a common and basic pathology in diabetes, however, antidiabetic drug often cause hypoglycemia, both increasing the range for glucose fluctuations. The level of glucose fluctuation is called glycemic variability (GV). Glycemic variability is now a favorite target of scientific research in diabetology. Increased glycemic variability is associated with hypoglycemia, possibly may contribute to chronic diabetes complications and negatively influences quality of life of diabetic patients. Last but not least, thanks to the new technology of continuous glucose monitoring, we can better describe and measure it. Finally, glycemic variability emerges as a potentially important therapeutical target.

Key words:
continuous glucose monitoring – glycemic variability – insulin pump – sensor augmented pump

Sources

1. Siegelaar SE et al. Glucose variability; does it matter? Endocr Rev 2010; 31(2): 171–182.

2. Sechterberger MK, Luijf YM, Devries JH. Poor agreement of computerized calculators for mean amplitude of glycemic excursions. Diabetes Technol Ther 2014; 16(2): 72–75.

3. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005; 54(6): 1615–1625.

4. Brownlee M, Hirsch IB. Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006; 295(14):1707–1708.

5. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J JAMA. 2006; 295(14): 1681–1687.

6. Ceriello A, Esposito K, Piconi L et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57(5): 1349–1354.

7. DCCT study group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–986.

8. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008; 31(11): 2198–2202.

9. Lachin JM1, Genuth S, Nathan DM et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial – revisited. Diabetes 2008; 57(4): 995–1001.

10. Bragd J, Adamson U, Bäcklund LBet al. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade Diabetes Metab 2008; 34(6 Pt 1): 612–616.

11. Siegelaar SE, Kilpatrick ES, Rigby AS et al. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: Data from the DCCT. Diabetologia 2009; 52(10): 2229–2232.

12. Su G, Mi S, Tao H et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 19. Dostupné z DOI: <http://doi: 10.1186/1475–2840–10–19>.

13. van den Berghe G, Wouters P, Weekers Fet al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345(19): 1359–1367.

14. Lanspa MJ, Dickerson J, Morris AH et al. Coefficient of glucose variation is independently associated with mortality in critically ill patients receiving intravenous insulin. Crit Care 2014; 18(2): R86.

15. Šoupal J1, Škrha J Jr, Fajmon M et al. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther 2014; 16(4): 198–203.

16. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care 2004; 27(3): 734–738.

17. Kilpatrick ES, Rigby AS, Goode K et al. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007; 50(12): 2553–2561.

18. Kovatchev BP, Cox DJ, Farhy LS et al. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab 2000; 85(11): 4287–4292.

19. Niskanen L, Virkamäki A, Hansen JB et al. Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study. Diabetes Res Clin Pract 2009; 86(2): e15-e18.

20. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2010; 39(3): 641–654.

21. Irace C, Fiorentino R, Carallo C et al. Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes. Diabetes Technol Ther 2011; 13(12): 1261–1263.

22. Yki-Järvinen H, Dressler A, Ziemen Met al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23(8): 1130–1136.

23. Evans M, Schumm-Draeger PM, Vora J et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011; 13(8): 677–684.

24. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805. Dostupné z DOI: <http://doi: 10.1136/bmj.d3805>.

25. Buse JB, Kudva YC, Battelino T et al. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther 2012; 14(7): 644–647.

26. Battelino T1, Phillip M, Bratina N et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011; 34(4): 795–800.

27. Kamble S, Weinfurt KP, Schulman KA et al. Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial. Med Decis Making 2013; 33(2): 215–224.

28. Elleri D1, Allen JM, Biagioni M et al. Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes. Pediatr Diabetes 2012; 13(6): 449–453.

29. Kumareswaran K, Elleri D, Allen JM, et al. Meta-analysis of overnight closed-loop randomized studies in children and adults with type 1 diabetes: the Cambridge cohort. J Diabetes Sci Technol 2011; 5(6): 1352–1362.

30. Elleri D, Allen JM, Kumareswaran K et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 2013; 36(4): 838–844.

31. Danne T, Kordonouri O, Holder M et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011; 13(11): 1129–1134.

32. Choudhary P, Shin J, Wang Y et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011; 34(9): 2023–2025.